Mopo Radebe1, Kamini Gounder, Mammekwa Mokgoro, Zaza M Ndhlovu, Zenele Mncube, Lungile Mkhize, Mary van der Stok, Manjeetha Jaggernath, Bruce D Walker, Thumbi Ndung'u. 1. aHIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal bKwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R. Mandela School of Medicine, Durban, South Africa cRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts dHoward Hughes Medical Institute, Maryland, USA eMax Planck Institute for Infection Biology, Charitestraße 1, Berlin, Germany.
Abstract
OBJECTIVE: We characterized protein-specific CD8 T-cell immunodominance patterns during the first year of HIV-1 infection, and their impact on viral evolution and immune control. METHODS: We analyzed CD8 T-cell responses to the full HIV-1 proteome during the first year of infection in 18 antiretroviral-naïve individuals with acute HIV-1 subtype C infection, all identified prior to seroconversion. Ex-vivo and cultured interferon-γ ELISPOT assays were performed and viruses from plasma were sequenced within defined CTL Gag epitopes. RESULTS: Nef-specific CD8 T-cell responses were dominant during the first 4 weeks after infection and made up 40% of the total responses at this time; yet, by 1 year, responses against this region had declined and Gag responses made up to 47% of all T-cell responses measured. An inverse correlation between the breadth of Gag-specific responses and viral load set point was evident at 26 weeks after infection (P = 0.0081, r = -0.60) and beyond. An inverse correlation between the number of persistent responses targeting Gag and viral set point was also identified (P = 0.01, r = -0.58). Gag-specific responses detectable by the cultured ELISPOT assay correlated negatively with viral load set point (P = 0.0013, r = -0.91). Sequence evolution in targeted and nontargeted Gag epitopes in this cohort was infrequent. CONCLUSIONS: These data underscore the importance of HIV-specific CD8 T-cell responses, particularly to the Gag protein, in the maintenance of low viral load levels during primary infection, and show that these responses are initially poorly elicited by natural infection. These data have implications for vaccine design strategies.
OBJECTIVE: We characterized protein-specific CD8 T-cell immunodominance patterns during the first year of HIV-1 infection, and their impact on viral evolution and immune control. METHODS: We analyzed CD8 T-cell responses to the full HIV-1 proteome during the first year of infection in 18 antiretroviral-naïve individuals with acute HIV-1 subtype C infection, all identified prior to seroconversion. Ex-vivo and cultured interferon-γ ELISPOT assays were performed and viruses from plasma were sequenced within defined CTL Gag epitopes. RESULTS:Nef-specific CD8 T-cell responses were dominant during the first 4 weeks after infection and made up 40% of the total responses at this time; yet, by 1 year, responses against this region had declined and Gag responses made up to 47% of all T-cell responses measured. An inverse correlation between the breadth of Gag-specific responses and viral load set point was evident at 26 weeks after infection (P = 0.0081, r = -0.60) and beyond. An inverse correlation between the number of persistent responses targeting Gag and viral set point was also identified (P = 0.01, r = -0.58). Gag-specific responses detectable by the cultured ELISPOT assay correlated negatively with viral load set point (P = 0.0013, r = -0.91). Sequence evolution in targeted and nontargeted Gag epitopes in this cohort was infrequent. CONCLUSIONS: These data underscore the importance of HIV-specific CD8 T-cell responses, particularly to the Gag protein, in the maintenance of low viral load levels during primary infection, and show that these responses are initially poorly elicited by natural infection. These data have implications for vaccine design strategies.
Authors: P Champagne; G S Ogg; A S King; C Knabenhans; K Ellefsen; M Nobile; V Appay; G P Rizzardi; S Fleury; M Lipp; R Förster; S Rowland-Jones; R P Sékaly; A J McMichael; G Pantaleo Journal: Nature Date: 2001-03-01 Impact factor: 49.962
Authors: Mathias Lichterfeld; Xu G Yu; Daniel Cohen; Marylyn M Addo; Jessica Malenfant; Beth Perkins; Eunice Pae; Mary N Johnston; Daryld Strick; Todd M Allen; Eric S Rosenberg; Bette Korber; Bruce D Walker; Marcus Altfeld Journal: AIDS Date: 2004-07-02 Impact factor: 4.177
Authors: M R Betts; D R Ambrozak; D C Douek; S Bonhoeffer; J M Brenchley; J P Casazza; R A Koup; L J Picker Journal: J Virol Date: 2001-12 Impact factor: 5.103
Authors: G Pantaleo; J F Demarest; H Soudeyns; C Graziosi; F Denis; J W Adelsberger; P Borrow; M S Saag; G M Shaw; R P Sekaly Journal: Nature Date: 1994-08-11 Impact factor: 49.962
Authors: Wendy A Burgers; Catherine Riou; Mandla Mlotshwa; Pholo Maenetje; Debra de Assis Rosa; Jason Brenchley; Koleka Mlisana; Daniel C Douek; Richard Koup; Mario Roederer; Guy de Bruyn; Salim Abdool Karim; Carolyn Williamson; Clive M Gray Journal: J Immunol Date: 2009-04-15 Impact factor: 5.422
Authors: M M Addo; X G Yu; A Rathod; D Cohen; R L Eldridge; D Strick; M N Johnston; C Corcoran; A G Wurcel; C A Fitzpatrick; M E Feeney; W R Rodriguez; N Basgoz; R Draenert; David R Stone; C Brander; P J R Goulder; E S Rosenberg; M Altfeld; B D Walker Journal: J Virol Date: 2003-02 Impact factor: 5.103
Authors: R Draenert; C L Verrill; Y Tang; T M Allen; A G Wurcel; M Boczanowski; A Lechner; A Y Kim; T Suscovich; N V Brown; M M Addo; B D Walker Journal: J Virol Date: 2004-01 Impact factor: 5.103
Authors: Mathias Lichterfeld; Daniel E Kaufmann; Xu G Yu; Stanley K Mui; Marylyn M Addo; Mary N Johnston; Daniel Cohen; Gregory K Robbins; Eunice Pae; Galit Alter; Alysse Wurcel; David Stone; Eric S Rosenberg; Bruce D Walker; Marcus Altfeld Journal: J Exp Med Date: 2004-09-20 Impact factor: 14.307
Authors: Marilia Rita Pinzone; Erin Graf; Lindsay Lynch; Brigit McLaughlin; Frederick M Hecht; Mark Connors; Stephen A Migueles; Wei-Ting Hwang; Giuseppe Nunnari; Una O'Doherty Journal: J Virol Date: 2016-11-14 Impact factor: 5.103
Authors: Santiago Avila-Rios; Jonathan M Carlson; Mina John; Simon Mallal; Zabrina L Brumme Journal: Curr Opin HIV AIDS Date: 2019-05 Impact factor: 4.283
Authors: Geetha H Mylvaganam; Lynette S Chea; Gregory K Tharp; Sakeenah Hicks; Vijayakumar Velu; Smita S Iyer; Claire Deleage; Jacob D Estes; Steven E Bosinger; Gordon J Freeman; Rafi Ahmed; Rama R Amara Journal: JCI Insight Date: 2018-09-20
Authors: Zaza M Ndhlovu; Samuel W Kazer; Thandeka Nkosi; Funsho Ogunshola; Daniel M Muema; Gursev Anmole; Shayda A Swann; Amber Moodley; Krista Dong; Tarylee Reddy; Mark A Brockman; Alex K Shalek; Thumbi Ndung'u; Bruce D Walker Journal: Sci Transl Med Date: 2019-05-22 Impact factor: 17.956
Authors: Esper G Kallas; Nicole A Grunenberg; Chenchen Yu; Bryce Manso; Giuseppe Pantaleo; Martin Casapia; Lindsey R Baden; Javier Valencia; Magdalena Sobieszczyk; Hong Van Tieu; Mary Allen; John Hural; Barney S Graham; James Kublin; Peter B Gilbert; Lawrence Corey; Paul A Goepfert; M Juliana McElrath; R Paul Johnson; Yunda Huang; Nicole Frahm Journal: Sci Transl Med Date: 2019-11-20 Impact factor: 17.956
Authors: Mark A Pilkinton; Wyatt J McDonnell; Louise Barnett; Abha Chopra; Rama Gangula; Katie D White; Shay Leary; Jennifer Currenti; Silvana Gaudieri; Simon A Mallal; Spyros A Kalams Journal: J Virol Date: 2021-02-03 Impact factor: 5.103
Authors: Feng Yun Yue; Jared C Cohen; Mu Ho; A K M Nur-Ur Rahman; Jun Liu; Shariq Mujib; Aamir Saiyed; Sabrina Hundal; Alexandra Khozin; Phil Bonner; Daheng Liu; Erika Benko; Colin Kovacs; Mario Ostrowski Journal: J Virol Date: 2017-03-29 Impact factor: 5.103
Authors: Jennifer S Sims; Boris Grinshpun; Yaping Feng; Timothy H Ung; Justin A Neira; Jorge L Samanamud; Peter Canoll; Yufeng Shen; Peter A Sims; Jeffrey N Bruce Journal: Proc Natl Acad Sci U S A Date: 2016-06-03 Impact factor: 11.205